Biofeedback for Psoriasis
NCT05506644 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2024-07-09
Summary
We are conducting a proof-of-concept trial to study the impact of HRV-biofeedback, a mind-body technique designed to improve stress resilience, on the quality of life, mood, and clinical skin severity of patients with psoriasis.
Conditions
- Psoriasis
- Psoriasis Vulgaris
- Psychophysiological Disorder
- Anxiety
- Depression
- Psychological Stress
- Physiological Stress
- Quality of Life
- Skin Disorder
- Skin Diseases
Interventions
- OTHER
-
HRV-Biofeedback/Mind-Body Therapy
A 7-week protocol using real-time feedback on heart rate variability
Sponsors & Collaborators
-
Bastyr University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-06-07
- Primary Completion
- 2022-12-31
- Completion
- 2023-03-31
Countries
- United States
Study Locations
More Related Trials
-
Psorcast Mobile Study
NCT05621369 ·Status: RECRUITING
-
Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis
NCT00001797 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
NCT04823247 ·Status: COMPLETED
-
Study of Psoriatic Arthritis
NCT00001420 ·Status: COMPLETED
-
SEquential Treatment of PSoriasis With Biologics
NCT07187817 ·Status: RECRUITING
-
Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling
NCT03795402 ·Status: COMPLETED
-
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
NCT01971346 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis
NCT01555606 ·Status: COMPLETED
-
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT02850965 ·Status: COMPLETED ·Phase: PHASE3
-
A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis
NCT03465696 ·Status: COMPLETED ·Phase: NA
-
Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.
NCT05046899 ·Status: COMPLETED ·Phase: NA
-
VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
NCT05655299 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis
NCT05547490 ·Status: COMPLETED
-
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
NCT05730725 ·Status: COMPLETED ·Phase: PHASE2
-
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
NCT01122095 ·Status: UNKNOWN
-
Brain Changes in Psoriasis After Secukinumab Treatment
NCT04717466 ·Status: COMPLETED ·Phase: PHASE4
-
Understanding Participation Habits Among Plaque Psoriasis Patients
NCT06338358 ·Status: NOT_YET_RECRUITING
-
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
NCT03718299 ·Status: COMPLETED ·Phase: PHASE4
-
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
NCT04340076 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
NCT02931838 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis
NCT00106834 ·Status: COMPLETED ·Phase: PHASE3
-
Personal Precise Treatment on Psoriasis and Psoriatic Arthritis
NCT04915105 ·Status: UNKNOWN ·Phase: NA
-
Premature Coronary Artery Disease (CAD) in Severe Psoriasis
NCT00893126 ·Status: COMPLETED
-
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
NCT07234591 ·Status: RECRUITING ·Phase: NA
-
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
NCT04999839 ·Status: COMPLETED ·Phase: PHASE2